Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in

Mauricio Lynn1, Igor Jerokhimov, Dory Jewelewicz

  • 1Division of Trauma and Surgical Critical Care, University of Miami School of Medicine, Miami, Florida 33101, USA.

The Journal of Trauma
|April 17, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is the Vermiform Appendix A "Safe House?": A Preliminary Examination of the Appendix Microbiome.

Shock (Augusta, Ga.)·2026
Same author

Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions.

International journal of molecular sciences·2023
Same author

Faecaliths do not predict severity of acute appendicitis.

The British journal of surgery·2022
Same author

Inferior Vena Cava Filters Lack Benefit in High-Risk Trauma Patients.

The American surgeon·2022
Same author

Emergency Ileostomies in Older Patients.

The American surgeon·2022
Same author

A CT-Derived Measurement of Sarcopenia Fails to Predict Falls.

The American surgeon·2022

Early administration of recombinant factor VIIa (rFVIIa) in experimental hepatic trauma showed a trend toward improved survival and reduced mortality. This treatment also improved hemodynamic parameters in swine.

Area of Science:

  • Hemorrhage control
  • Trauma resuscitation
  • Hemostasis

Background:

  • Recombinant factor VIIa (rFVIIa) is a treatment for hemophilia patients with inhibitors.
  • Investigating rFVIIa's efficacy in managing bleeding after hepatic trauma.

Purpose of the Study:

  • To test if early rFVIIa administration decreases bleeding and improves survival in experimental hepatic trauma.
  • To evaluate the impact of rFVIIa on hemodynamic stability post-injury.

Main Methods:

  • Swine model of hepatic avulsion-induced hemorrhage.
  • Randomized trial comparing intravenous rFVIIa (180 microg/kg) versus placebo.
  • Hemodynamic monitoring and blood sampling.

Main Results:

Related Experiment Videos

  • Zero mortality in the rFVIIa group versus 43% in the placebo group (p=0.08).
  • Significantly shorter prothrombin time in the rFVIIa group.
  • Higher mean arterial pressures observed with rFVIIa treatment.

    • Conclusions:

    • Early intravenous rFVIIa administration improves hemodynamic parameters after hepatic trauma.
    • A trend towards improved survival suggests potential benefit in managing severe hemorrhage.